Clinical Trials Directory

Trials / Conditions / Recurrent Hematologic Malignancy

Recurrent Hematologic Malignancy

8 registered clinical trials studyying Recurrent Hematologic Malignancy.

StatusTrialSponsorPhase
CompletedDistress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Can
NCT05058339
M.D. Anderson Cancer Center—
CompletedFlotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
NCT04681105
City of Hope Medical CenterPhase 1
TerminatedIrradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig
NCT03272633
Rutgers, The State University of New JerseyEARLY_Phase 1
WithdrawnFlotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
NCT03739606
City of Hope Medical CenterPhase 2
TerminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT03878524
OHSU Knight Cancer InstitutePhase 1
CompletedFructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT02805075
Stanford UniversityPhase 1
SuspendedIntensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With R
NCT02333162
University of ChicagoPhase 1
CompletedIpilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran
NCT01822509
National Cancer Institute (NCI)Phase 1